Table 2. Response rates and duration in... | American Society of Hematology

Table 2.

Response rates and duration in subcategories of patients in the long-term follow-up of 3 studies on treatment with Epo and G-CSF

Group	Total no. patients	No. responding patients	RR, %	CER, %	PER, %	Median response duration, mo (range)*	P
All	123	48	39	22	17	23 (3-116)	—
Complete responders	27	NA	NA	NA	NA	29 (4-116)	.006
Partial responders	21	NA	NA	NA	NA	12 (3-93)	—
FAB
RA	28	11	39	18	21	27 (4-62)	.83†
RARS	40	20	50	38	13	28 (3-116)	—
RA + RARS	68	31	46	29	16	28 (3-116)	.04‡
RAEB	55	17	31	13	18	11 (3-93)	—
IPSS
Low/Int-1	88	40	46	27	18	25 (3-116)	.002
Int-2/High	26	7	27	12	15	7 (3-23)	—
Predictive group for response
Good	42	25	60	36	24	24 (3-116)	.95§
Intermediate	44	8	18	9	9	23 (4-93)	—
Poor	16	1	6	0	6	3∥	—

Group	Total no. patients	No. responding patients	RR, %	CER, %	PER, %	Median response duration, mo (range)*	P
All	123	48	39	22	17	23 (3-116)	—
Complete responders	27	NA	NA	NA	NA	29 (4-116)	.006
Partial responders	21	NA	NA	NA	NA	12 (3-93)	—
FAB
RA	28	11	39	18	21	27 (4-62)	.83†
RARS	40	20	50	38	13	28 (3-116)	—
RA + RARS	68	31	46	29	16	28 (3-116)	.04‡
RAEB	55	17	31	13	18	11 (3-93)	—
IPSS
Low/Int-1	88	40	46	27	18	25 (3-116)	.002
Int-2/High	26	7	27	12	15	7 (3-23)	—
Predictive group for response
Good	42	25	60	36	24	24 (3-116)	.95§
Intermediate	44	8	18	9	9	23 (4-93)	—
Poor	16	1	6	0	6	3∥	—

RR indicates response rate; NA, not applicable.

Only for the 41 patients entering the maintenance phase.

P value of RA versus RARS.

P value of RA + RARS versus RAEB.

P value of predictive group good versus intermediate.

There is no range because this figure represents one patient.